United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - poloxamer 188; dantron - oral suspension - 200mg/1ml ; 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

focus pharmaceuticals ltd - poloxamer 188; dantron - oral suspension - 200mg/1ml ; 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - poloxamer 188; dantron - oral suspension - 200mg/1ml ; 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sovereign medical ltd - poloxamer 188; dantron - oral suspension - 200mg/1ml ; 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - poloxamer 188; dantron - oral suspension - 200mg/1ml ; 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - docusate sodium; dantron - oral suspension - 12mg/1ml ; 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - docusate sodium; dantron - oral suspension - 12mg/1ml ; 10mg/1ml

Canada - English - Health Canada

whitehall-robins inc. - danthron; docusate sodium - capsule - 50mg; 60mg - danthron 50mg; docusate sodium 60mg - cathartics and laxatives

Canada - English - Health Canada

smithkline beecham pharma division of smithkline beecham inc - danthron; docusate sodium - tablet - 50mg; 60mg - danthron 50mg; docusate sodium 60mg - cathartics and laxatives

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - dantrolene sodium (unii: 287m0347ev) (dantrolene - unii:f64qu97qcr) - dantrolene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. if improvement occurs, it will ordinarily occur within the dosage titration (see dosage and administration ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium. occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. in such instances, information regarding improvement should be solicited fro